Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001104659-26-020540
Filing Date
2026-02-26
Accepted
2026-02-26 16:31:23
Documents
81
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K acrs-20251231x10k.htm   iXBRL 10-K 2789274
2 EX-4.1 acrs-20251231xex4d1.htm EX-4.1 22307
3 EX-23.1 acrs-20251231xex23d1.htm EX-23.1 3457
4 EX-31.1 acrs-20251231xex31d1.htm EX-31.1 9584
5 EX-31.2 acrs-20251231xex31d2.htm EX-31.2 9700
6 EX-32.1 acrs-20251231xex32d1.htm EX-32.1 9334
7 GRAPHIC acrs-20251231x10k002.jpg GRAPHIC 83122
  Complete submission text file 0001104659-26-020540.txt   9992713

Data Files

Seq Description Document Type Size
8 EX-101.SCH acrs-20251231.xsd EX-101.SCH 57561
9 EX-101.CAL acrs-20251231_cal.xml EX-101.CAL 63829
10 EX-101.DEF acrs-20251231_def.xml EX-101.DEF 211564
11 EX-101.LAB acrs-20251231_lab.xml EX-101.LAB 590147
12 EX-101.PRE acrs-20251231_pre.xml EX-101.PRE 392446
85 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20251231x10k_htm.xml XML 1522156
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37581 | Film No.: 26689412
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)